# **The Corvus Pharmaceuticals (CRVS) 2026 Strategic Analysis: Soquelitinib and the Paradigm Shift in Atopic Dermatitis**

## **1\. Executive Strategic Assessment**

### **1.1 The January 2026 Inflection Point**

The biopharmaceutical landscape currently stands at a critical juncture regarding the treatment of immune-mediated inflammatory diseases (IMID), specifically Atopic Dermatitis (AD). As of January 2026, **Corvus Pharmaceuticals** (CRVS) is approaching a defining binary event: the release of topline data from **Cohort 4** of its Phase 1 clinical trial for **soquelitinib**. This report provides an exhaustive analysis of the company’s strategic positioning, predicated on the hypothesis that **soquelitinib**—an oral, selective inhibitor of IL-2-inducible T-cell kinase (ITK)—represents a disruptive "breakout" asset capable of bridging the efficacy-safety gap that currently **bifurcates** the dermatology market.

The central thesis of this analysis posits that the prevailing standard of care (**SoC**) is polarized between highly efficacious but safety-compromised **Janus Kinase (JAK)** inhibitors and highly safe but **administration-heavy biologics**. The market has long sought an oral agent that delivers biologic-like safety with **JAK-like efficacy**. Based on the data synthesis from 2025, specifically the Cohort 3 results showing a **71.1% mean reduction in EASI scores** at 4 weeks 1, soquelitinib appears poised to occupy this "Goldilocks" zone.

This report evaluates the probability of a "breakout" scenario for the Cohort 4 readout (200mg BID, 8-week duration) and models its implications for the company's valuation through 2027\. By integrating clinical data, competitive benchmarking against Sanofi’s amlitelimab and AbbVie’s Rinvoq, and deep translational immunology insights from pivotal studies by **Miller et al. (2025)** and **McLane et al.**, we construct a risk-adjusted outlook for the asset.

### **1.2 The "Breakout" Definition and Valuation Impact**

For the purpose of this strategic analysis, a "breakout" is not merely defined by statistical significance against placebo—a low bar given the known efficacy of ITK inhibition. Rather, a breakout is defined by three specific clinical signals in the upcoming 8-week data:

1. **Kinetic Deepening:** A mean EASI percentage reduction exceeding **75%**, demonstrating that the 71.1% observed at Week 4 was a point on an upward trajectory rather than a plateau.  
2. **Immunologic Durability:** A lack of rapid symptom rebound during the 30-day washout period, differentiating the drug from the receptor-blockade mechanism of JAK inhibitors.  
3. **Safety Preservation:** Maintenance of the clean safety profile (zero Grade 3+ adverse events, no lymphopenia) over double the exposure duration.

The valuation implications of such a readout are profound. Current market capitalization reflects a "wait-and-see" approach, largely attributing value to the oncology (PTCL) pipeline. A breakout in AD validates soquelitinib as a "pipeline-in-a-product" applicable to a broad range of Th2/Th17-driven autoimmune diseases (e.g., asthma, psoriasis, systemic sclerosis).3 This would necessitate a fundamental re-rating of Corvus from a niche oncology player to a major immunology platform company, likely triggering intense partnership interest from large pharma entities seeking to protect their immunology franchises from the patent cliffs of the late 2020s.

## ---

**2\. Part 1: Clinical Data Synthesis & Dose-Response Analysis**

The predictive validity of this report rests on a granular analysis of the existing clinical dataset. To forecast the Cohort 4 (8-week) results, we must first dissect the baseline established by Cohort 3 (4-week).

### **2.1 The Baseline: Deconstructing Cohort 3 (200mg BID, 4 Weeks)**

In mid-2025, Corvus released interim data from Cohort 3, which utilized a dosage of 200mg twice daily (BID). This cohort provided the first definitive proof-of-concept for high-dose ITK inhibition in humans with moderate-to-severe AD.

**Comparative Efficacy Analysis (Day 28):**

| Endpoint | Soquelitinib (200mg BID) | Placebo | Delta | Statistical Significance | Source |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Mean EASI % Reduction** | **71.1%** | 42.1% | \+29.0% | $p \< 0.05$ | 1 |
| **EASI-75 Response** | **63.0%** | 0.0% | \+63.0% | Significant | 1 |
| **IGA 0/1 (Clear/Almost Clear)** | **35.0%** | 0.0% | \+35.0% | Significant | 5 |

Analysis of the 71.1% Signal:  
The 71.1% mean reduction in Eczema Area and Severity Index (EASI) scores at just 28 days is a highly competitive signal. To contextualize this:

* **Dupixent (Dupilumab):** Typically achieves a \~70% mean reduction at **Week 16** in monotherapy trials (SOLO 1/2).6  
* **Rinvoq (Upadacitinib):** The 15mg dose achieves \~70% EASI-75 response rates at Week 16, with rapid onset.7  
* **Implication:** Soquelitinib achieving biologic-level depth of response in one-fourth of the time (4 weeks vs. 16 weeks) suggests a potent interruption of the inflammatory cascade.

The placebo rate in Cohort 3 (42.1% mean reduction) was notably high, a common phenomenon in AD trials where emollients (moisturizers) are used as background therapy.1 However, the **Responder Analysis** provides the true signal-to-noise ratio: **0% of placebo patients achieved EASI-75**, compared to **63% of soquelitinib patients**.5 This stark separation confirms the drug's activity is driving the high-end clearance, not background care.

### **2.2 Forecasting Cohort 4: The Kinetics of Th2-to-Th1 Skewing**

The primary objective of Cohort 4 is to extend the treatment duration to 8 weeks. The critical academic question is whether the response curve plateaus or deepens.

The "Plateau vs. Deepening" Hypothesis:  
Most immunomodulators in AD show a continuous deepening of response through Week 12 or Week 16\.

* **Mechanism of Action (MoA) Impact:** Soquelitinib works by inhibiting ITK, which drives the differentiation of naive T-cells into Th2 (pro-inflammatory) cells. Inhibition skews this differentiation towards Th1 (anti-viral/anti-tumor) and Treg (tolerance) phenotypes.8  
* **Cellular Turnover:** This "skewing" is a biological process dependent on the turnover of existing T-cell populations in the skin. The 4-week data likely reflects the inhibition of acute cytokine signaling and the initial wave of T-cell repopulation.  
* **Projection:** Extending to 8 weeks allows for a more complete replacement of pathogenic Th2 cells with the benign/protective Th1/Treg phenotype. Therefore, we project a **deepening of the EASI reduction to the 75-82% range** at Week 8\. If the data shows a plateau at \~70%, it would suggest the drug acts more as a symptom suppressant than a disease modifier. However, the biology of T-cell turnover supports the deepening hypothesis.

**Table 5: Projected Cohort 4 Outcomes vs. Benchmarks**

| Metric | Cohort 3 (Actual \- 4 Wks) | Cohort 4 (Projected \- 8 Wks) | Rinvoq 15mg (16 Wks) | Dupixent (16 Wks) |
| :---- | :---- | :---- | :---- | :---- |
| **Mean EASI Red.** | 71.1% | **\~78-82%** | \~70-75% | \~70% 6 |
| **EASI-75** | 63% | **\~70-75%** | 70% 7 | 53% 6 |
| **IGA 0/1** | 35% | **\~45-50%** | 48% 7 | 28% 6 |

### **2.3 The "Itch-Free" (Pruritus NRS) Kinetics**

Pruritus (itch) is the most burdensome symptom for patients and a key driver of prescription adherence.

* **Data So Far:** Cohort 3 demonstrated "clinically meaningful reduction in itch as early as Day 8".10  
* **Mechanism:** Itch in AD is driven largely by IL-31, a cytokine produced by Th2 cells. Since ITK inhibition blocks Th2 differentiation and cytokine production (including IL-31)5, the reduction in itch is a direct downstream effect of target engagement.  
* **Cohort 4 Watch Item:** We must look for a separation from placebo in the **Peak Pruritus NRS (PP-NRS)** score by Day 8, maintained through Week 8\.  
* **Benchmarking:** JAK inhibitors are famous for their rapid anti-itch effect (often within 2 days).12 If soquelitinib can match the *magnitude* of itch relief by Week 2-4, even if slightly slower than the 2-day JAK onset, it represents a massive win given the superior safety profile.

### **2.4 The "Durability" Question: Rebound vs. Remission**

One of the most critical aspects of the upcoming readout is the 30-day non-treatment follow-up period. This phase distinguishes "suppressive" therapies from "modulatory" therapies.

The JAK Rebound Effect:  
JAK inhibitors (e.g., upadacitinib, abrocitinib) function by blocking the signaling receptor on the cell surface. They do not fundamentally alter the cell's identity.

* **Pathology of Rebound:** When a JAK inhibitor is withdrawn, the body often experiences a "rebound phenomenon." The blockade of cytokine signaling can lead to a compensatory upregulation of cytokine receptors or accumulated pruritogenic cytokines. Once the inhibitor clears the system, symptoms can flare rapidly.13  
* **Clinical Reality:** This necessitates continuous dosing, as seen in real-world relapse rates for JAK inhibitors (median time to relapse \~18 days for upadacitinib).15

The ITK "Sustained Effect":  
Soquelitinib’s mechanism posits a different outcome. By inhibiting ITK, the drug induces a phenotypic switch:

1. **Th2 Depletion:** The pathogenic cells driving the disease are reduced.  
2. **Treg Expansion:** Regulatory T-cells are expanded.8  
* **Prediction for Cohort 4 Follow-Up:** Upon cessation of soquelitinib at Week 8, we expect to see a **sustained maintenance of EASI scores** during the 30-day washout. Unlike JAKs, there should be no catastrophic flare.  
* **Evidence:** Management has already signaled "durable post-treatment results" in earlier cohorts.1 Confirming this in the larger, longer Cohort 4 is vital. If confirmed, this supports the claim that soquelitinib induces a state of *remission* or *tolerance*, potentially allowing for intermittent dosing.

## ---

**3\. Part 2: Comparative Competitive Landscape & "Standard of Care" Bar**

The valuation of Corvus depends on where soquelitinib fits into the crowded AD treatment algorithm. We benchmark against the two dominant classes: Biologics (Injectable) and JAK Inhibitors (Oral).

### **3.1 Benchmark vs. Biologics (Dupixent / Amlitelimab)**

Standard of Care: Dupixent (dupilumab) is the current king.  
Emerging Challenger: Amlitelimab (anti-OX40L, Sanofi) is the next-gen biologic, promising durability.  
**Key Question:** Can an oral small molecule match the efficacy of these biologics?

* **Efficacy Comparison:**  
  * **Dupilumab:** EASI-75 at Week 16 is **\~48-53%**.6  
  * **Amlitelimab:** EASI-75 at Week 24 ranges from **39% to 59%** depending on dose.18  
  * **Soquelitinib (Cohort 3):** EASI-75 at Week 4 was **63%**.1  
* **Strategic Insight:** Soquelitinib is already numerically superior to Dupixent’s *pivotal* 16-week numbers at just 4 weeks. If the 8-week Cohort 4 data holds \>60-65% EASI-75, soquelitinib becomes a "Bio-Superior Oral."

The Amlitelimab Factor (Durability):  
Sanofi’s amlitelimab data highlighted "sustained maintenance" off-drug.19 This "durability" is the new battleground. Soquelitinib achieves this via Treg expansion.

* **Implication:** To compete with Amlitelimab’s maintenance potential, soquelitinib must prove that its oral dosing provides a similar "immunological reset." The 30-day follow-up data in Cohvus's Cohort 4 is the proxy for this comparison.

### **3.2 Benchmark vs. JAK Inhibitors (Rinvoq / Cibinqo)**

**Standard of Care:** Rinvoq (upadacitinib) and Cibinqo (abrocitinib) are efficacy leaders but shackled by safety warnings.

**Key Question:** Does soquelitinib maintain a "clean" safety profile to avoid the "Black Box"?

* **The "Black Box" Reality:** JAK inhibitors carry boxed warnings for **MACE**, **Thrombosis**, **Malignancy**, and **Serious Infections**.20  
  * **Rinvoq Safety:** Associated with lymphopenia (\<500 cells/µL), anemia, and CPK elevations.21  
  * **Cibinqo Safety:** Associated with dose-dependent thrombocytopenia (platelet reduction).22  
* **Soquelitinib Profile:**  
  * **Lymphopenia:** In all cohorts to date, plus the oncology trials, soquelitinib has shown **no evidence of lymphopenia**.23 In fact, it requires a baseline level of immunocompetence to work.24  
  * **Malignancy:** While JAKs *cause* malignancy concerns, soquelitinib *treats* malignancy (T-cell lymphoma). This creates a paradoxical "Safety Moat."  
  * **Infection:** JAKs increase herpes zoster (shingles) rates markedly.20 Soquelitinib, by sparing Th1 function (anti-viral immunity), should not show this signal.  
* **Observation:** The market rewards "JAK-like efficacy with Biologic-like safety." If Cohort 4 confirms \>70% EASI-75 with zero Grade 3 AEs and no lab abnormalities, soquelitinib effectively renders the JAK class obsolete for first-line oral therapy.

## ---

**4\. Part 3: Scientific Probability of Success (PoS) Indicators**

This section addresses the deep biological validation, analyzing the mechanistic underpinnings that support the probability of success.

### **4.1 Biomarker Analysis: ITK Occupancy and Treg Expansion**

The user specifically asks for correlations between ITK occupancy and Treg expansion in humans.

Mechanism (The Rheostat vs. The Switch):  
Unlike JAKs, which act as an "off switch" for cytokine signaling, ITK acts as a "rheostat" for T-cell Receptor (TCR) signal strength.

* **High Signal Strength:** Drives Th2 and Th17 differentiation (pro-inflammatory).  
* **Modulated Signal Strength (ITK Inhibition):** Drives Foxp3+ Treg differentiation (anti-inflammatory/tolerance).  
* **Evidence:** Preclinical studies8 and Corvus’s translational data11 indicate that soquelitinib treatment leads to a measurable increase in circulating Foxp3+ Tregs and a reduction in Th2 cytokines (IL-5, IL-13).  
* **Strategic PoS Indicator:** In the Cohort 4 readout, investors should look for biomarker data confirming an increase in the **Treg:Th17 ratio**. This ratio is a more potent predictor of long-term remission than cytokine levels alone.

### **4.2 Translational Insight: The McLane/Miller Connection**

The user references academic findings on ITK inhibition. The foundational science for Corvus is deeply rooted in the work of its founders and collaborators (Miller et al.).

**Key Findings:**

1. **Reversal of Exhaustion:** Studies demonstrated that ITK inhibition can reverse CD8+ T-cell exhaustion.25  
2. **Application to AD Skin Microenvironment:** In Atopic Dermatitis, the skin is infiltrated by chronically activated, yet dysregulated, Th2 cells.  
   * **Translation:** By modulating ITK, soquelitinib prevents the aberrant hyper-activation of Th2 cells in the dermis while simultaneously boosting the "healthy" surveillance capacity of Th1/CD8+ cells.9 This dual action—suppressing the bad (Th2) while reinvigorating the good (Th1/CD8)—explains why the drug creates durable responses without immunosuppression.

### **4.3 The "Safety Moat": Selective Inhibition (ITK vs. RLK/BTK)**

The safety of kinase inhibitors is entirely dependent on selectivity.

* **The Target:** ITK.  
* **The Avoidance Targets:** RLK (Resting Lymphocyte Kinase) and BTK.  
* **Why it Matters:**  
  * **RLK Sparing:** RLK is a redundant kinase in T-cells. If a drug hits *both* ITK and RLK, it shuts down T-cell signaling completely, leading to severe immunosuppression (SCID-like phenotype). Soquelitinib is highly selective for ITK (\>100-fold vs RLK).25 This "sparing" of RLK allows the immune system to retain basal functionality.  
  * **BTK Sparing:** Avoiding BTK prevents the bleeding risks and B-cell depletion seen with drugs like ibrutinib.  
* **Cohort 4 Verification:** The 33% total AE rate (mostly Grade 1\) seen in earlier data5 must be maintained.

### **4.4 PK/PD Analysis: The Shift to 200mg BID**

The user asks about the comparison between 200mg BID and the canceled 400mg QD.

* **Observation:** Cohort 3 (200mg BID) showed "earlier and deeper responses" than Cohort 2 (200mg QD).10  
* **Pharmacokinetic Reason:** ITK requires sustained occupancy to prevent T-cell differentiation. A once-daily (QD) dose likely allowed for a "trough" period where drug levels dropped below the IC50, allowing a window for Th2 signaling to resume.  
* **Strategy:** The BID regimen ensures constant pressure on the target, maintaining the "skewing" signal 24/7.

## ---

**5\. Part 4: Oncology Cross-Read & Safety Validation**

A unique aspect of the Corvus thesis is the concurrent development of soquelitinib for Peripheral T-Cell Lymphoma (PTCL).

### **5.1 The ASH 2025 Data (Miller et al.)**

The final data from the Phase 1/1b PTCL trial presented at ASH 2025 is a massive de-risking event for the AD program.27

* **Safety in the Sickest:** The PTCL trial enrolled heavily pre-treated, immunocompromised patients. Even in this fragile population, soquelitinib showed **no dose-limiting toxicities (DLTs)** and no significant myelosuppression (anemia/neutropenia) up to 600mg BID.23  
* **Strategic Implication:** If a drug does not cause cytopenias in lymphoma patients (whose bone marrow is already under stress), it is statistically highly improbable to cause them in healthy dermatology patients. This effectively rules out the hematological toxicity risks that plague JAK inhibitors.  
* **Mechanism Validation:** The trial showed "Objective Responses" and prolonged survival.27 This proves that the molecule *works*—it engages ITK, modulates T-cells, and induces an anti-tumor immune response (Th1 skewing).

## ---

**6\. Valuation & 2026 Outlook**

### **6.1 The "Breakout" Valuation Model**

Current valuation (\~$570M-$630M market cap)28 assigns minimal value to the AD program. A breakout in Cohort 4 changes the math entirely.

* **Target Market:** The global AD market is \>$15B. The "Oral" segment is currently dominated by Rinvoq/Cibinqo despite safety baggage.  
* **Soquelitinib Peak Sales:** If soquelitinib is confirmed as a "Clean Oral" with \>75% EASI reduction:  
  * **Conservative:** $1.5B (Displacing second-line JAKs).  
  * **Bull Case:** $3-5B (First-line oral, displacing mild-moderate biologic use).  
* **2026 Catalyst Path:**  
  * **Jan 2026:** Cohort 4 Data (The Breakout Event).28  
  * **Q1 2026:** Initiation of Phase 2b Dose-Ranging Trial.31  
  * **2H 2026:** Potential partnership deal. Big Pharma (e.g., Sanofi, AbbVie, Pfizer) is actively seeking "JAK replacements."

### **6.2 Conclusion**

The **Corvus Pharmaceuticals** story in 2026 is one of **paradigm shift**. The clinical data from 2025 has laid the foundation: soquelitinib is active, rapid, and potent. The Cohort 4 readout is the final verification step.

If the 8-week data confirms the **deepening of efficacy (\>75% EASI)** and the **durability of the Treg response**, soquelitinib will effectively decouple "efficacy" from "toxicity" in the oral dermatology market. The scientific convergence of the Miller (ASH 2025\) and McLane datasets provides a robust biological rationale for this profile. As such, the probability of a breakout is substantial, positioning Corvus for a transformative valuation event in early 2026\.

### **Table 6: Summary of Strategic "Watch-Items" for Cohort 4**

| Strategic Metric | Threshold for "Breakout" | Current Benchmark | Strategic Implication |
| :---- | :---- | :---- | :---- |
| **Week 8 Mean EASI Reduction** | **\> 75%** | Cohort 3 (4wk): 71.1% | Confirms kinetic deepening; challenges high-dose JAKs. |
| **Week 8 EASI-75 Rate** | **\> 70%** | Rinvoq 15mg: \~70% | Establishes "JAK-like" efficacy equivalence. |
| **Day 58 (Washout) EASI** | **Maintain \<10% Loss** | JAKs: Rapid Rebound | Validates "Disease Modification" & Treg durability. |
| **Safety: Lymphopenia/Infection** | **0% / Placebo-like** | JAKs: Elevated Risk | Cements the "Safety Moat" vs. Black Box agents. |
| **Pruritus (NRS4) Onset** | **Separation by Day 8** | JAKs: Day 2-3 | Critical for patient adherence and quality of life marketing. |

#### **Works cited**

1. Dermatitis data: LEO Pharma, Corvus candidates progress, accessed on January 10, 2026, [https://firstwordpharma.com/story/5959212](https://firstwordpharma.com/story/5959212)  
2. Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript | Seeking Alpha, accessed on January 10, 2026, [https://seekingalpha.com/article/4784124-corvus-pharmaceuticals-inc-crvs-q1-2025-earnings-call-transcript](https://seekingalpha.com/article/4784124-corvus-pharmaceuticals-inc-crvs-q1-2025-earnings-call-transcript)  
3. Soquelitinib, A Selective Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK), is Active in Several Murine Models of T Cell-Mediated Inflammatory Disease | bioRxiv, accessed on January 10, 2026, [https://www.biorxiv.org/content/10.1101/2023.10.27.564296v1.full-text](https://www.biorxiv.org/content/10.1101/2023.10.27.564296v1.full-text)  
4. Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis, accessed on January 10, 2026, [https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-new-preclinical-data](https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-new-preclinical-data)  
5. Corvus Pharmaceuticals' Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial | Dermatology Times, accessed on January 10, 2026, [https://www.dermatologytimes.com/view/corvus-pharmaceuticals-soquelitinib-shows-rapid-dose-dependent-efficacy-in-phase-1-ad-trial](https://www.dermatologytimes.com/view/corvus-pharmaceuticals-soquelitinib-shows-rapid-dose-dependent-efficacy-in-phase-1-ad-trial)  
6. Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months \- Sanofi, accessed on January 10, 2026, [https://www.sanofi.com/en/media-room/press-releases/2021/2021-08-30-05-00-00-2288011](https://www.sanofi.com/en/media-room/press-releases/2021/2021-08-30-05-00-00-2288011)  
7. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials \- PubMed, accessed on January 10, 2026, [https://pubmed.ncbi.nlm.nih.gov/34023008/](https://pubmed.ncbi.nlm.nih.gov/34023008/)  
8. Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases | Corvus Pharmaceuticals, accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/publication-preclinical-data-science-signaling-demonstrated/](https://investor.corvuspharma.com/news-releases/news-release-details/publication-preclinical-data-science-signaling-demonstrated/)  
9. Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818), accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-publication-preclinical-data/](https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-publication-preclinical-data/)  
10. Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results, accessed on January 10, 2026, [https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-provides-business-update-and-reports-24](https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-provides-business-update-and-reports-24)  
11. Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis, accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-data-cohorts-1-3-placebo/](https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-data-cohorts-1-3-placebo/)  
12. New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study \- Apr 25, 2024 \- AbbVie News Center, accessed on January 10, 2026, [https://news.abbvie.com/2024-04-25-New-Data-Show-RINVOQ-R-upadacitinib-Demonstrated-Superiority-Versus-DUPIXENT-R-dupilumab-Across-Primary-and-All-Secondary-Endpoints-in-an-Open-Label-Head-to-Head-Atopic-Dermatitis-Study](https://news.abbvie.com/2024-04-25-New-Data-Show-RINVOQ-R-upadacitinib-Demonstrated-Superiority-Versus-DUPIXENT-R-dupilumab-Across-Primary-and-All-Secondary-Endpoints-in-an-Open-Label-Head-to-Head-Atopic-Dermatitis-Study)  
13. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib \- FDA \- Research Portal, accessed on January 10, 2026, [https://fda-researchportal.esploro.exlibrisgroup.com/view/pdfCoverPage?instCode=01FDA\_INST\&filePid=1368386170003806\&download=true](https://fda-researchportal.esploro.exlibrisgroup.com/view/pdfCoverPage?instCode=01FDA_INST&filePid=1368386170003806&download=true)  
14. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib | Request PDF \- ResearchGate, accessed on January 10, 2026, [https://www.researchgate.net/publication/310050029\_Demonstration\_of\_rebound\_phenomenon\_following\_abrupt\_withdrawal\_of\_the\_JAK1\_inhibitor\_oclacitinib](https://www.researchgate.net/publication/310050029_Demonstration_of_rebound_phenomenon_following_abrupt_withdrawal_of_the_JAK1_inhibitor_oclacitinib)  
15. FAQ – Rinvoq (Upadacitinib) | National Eczema Association, accessed on January 10, 2026, [https://nationaleczema.org/faq-upadacitinib/](https://nationaleczema.org/faq-upadacitinib/)  
16. Form 8-K for Corvus Pharmaceuticals INC filed 05/08/2025, accessed on January 10, 2026, [https://corvuspharma.gcs-web.com/static-files/3e248d4a-e8a5-457d-a95e-bfe770dd105c](https://corvuspharma.gcs-web.com/static-files/3e248d4a-e8a5-457d-a95e-bfe770dd105c)  
17. Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis \- Regeneron Investor Relations, accessed on January 10, 2026, [https://newsroom.regeneron.com/news-releases/news-release-details/positive-phase-3-results-presented-dupixentr-dupilumab-show/](https://newsroom.regeneron.com/news-releases/news-release-details/positive-phase-3-results-presented-dupixentr-dupilumab-show/)  
18. Press Release: New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis \- Sanofi, accessed on January 10, 2026, [https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-30-12-30-00-2306183](https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-30-12-30-00-2306183)  
19. Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis \- Sanofi, accessed on January 10, 2026, [https://www.sanofi.com/en/media-room/press-releases/2024/2024-03-11-06-00-00-2843456](https://www.sanofi.com/en/media-room/press-releases/2024/2024-03-11-06-00-00-2843456)  
20. RINVOQ® (upadacitinib) Safety Data, accessed on January 10, 2026, [https://www.rinvoqhcp.com/dermatology/safety](https://www.rinvoqhcp.com/dermatology/safety)  
21. RINVOQ® (upadacitinib) Results for Adults with Eczema (Atopic Dermatitis), accessed on January 10, 2026, [https://www.rinvoq.com/atopic-dermatitis/rinvoq-results/results-with-rinvoq](https://www.rinvoq.com/atopic-dermatitis/rinvoq-results/results-with-rinvoq)  
22. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis \- NIH, accessed on January 10, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11264490/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11264490/)  
23. Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial, accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-final-data-soquelitinib-phase/](https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-final-data-soquelitinib-phase/)  
24. Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL) | Blood | American Society of Hematology \- ASH Publications, accessed on January 10, 2026, [https://ashpublications.org/blood/article/146/Supplement%201/778/556105/Final-results-of-a-phase-1-trial-with-soquelitinib](https://ashpublications.org/blood/article/146/Supplement%201/778/556105/Final-results-of-a-phase-1-trial-with-soquelitinib)  
25. Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing \- bioRxiv, accessed on January 10, 2026, [https://www.biorxiv.org/content/10.1101/2023.07.05.547822v1.full.pdf](https://www.biorxiv.org/content/10.1101/2023.07.05.547822v1.full.pdf)  
26. Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights \- PMC, accessed on January 10, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8131230/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8131230/)  
27. Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial, accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-final-data-soquelitinib-phase](https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-final-data-soquelitinib-phase)  
28. Corvus Pharmaceuticals stock awaits key January 2026 trial data \- Investing.com, accessed on January 10, 2026, [https://www.investing.com/news/analyst-ratings/corvus-pharmaceuticals-stock-awaits-key-january-2026-trial-data-93CH-4403230](https://www.investing.com/news/analyst-ratings/corvus-pharmaceuticals-stock-awaits-key-january-2026-trial-data-93CH-4403230)  
29. The ITK inhibitor caused an elevation in Treg-related signaling in the... \- ResearchGate, accessed on January 10, 2026, [https://www.researchgate.net/figure/The-ITK-inhibitor-caused-an-elevation-in-Treg-related-signaling-in-the-periphery-and-CNS\_fig5\_370461482](https://www.researchgate.net/figure/The-ITK-inhibitor-caused-an-elevation-in-Treg-related-signaling-in-the-periphery-and-CNS_fig5_370461482)  
30. Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference, accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-confirms-plans-announce-results-cohort-4](https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-confirms-plans-announce-results-cohort-4)  
31. Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results, accessed on January 10, 2026, [https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-provides-business-update-and-reports-25](https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-provides-business-update-and-reports-25)